Is Now An Opportune Moment To Examine Intersect ENT, Inc. (NASDAQ:XENT)?

By
Simply Wall St
Published
June 08, 2021
NasdaqGM:XENT
Source: Shutterstock

While Intersect ENT, Inc. (NASDAQ:XENT) might not be the most widely known stock at the moment, it received a lot of attention from a substantial price movement on the NASDAQGM over the last few months, increasing to US$24.33 at one point, and dropping to the lows of US$16.46. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Intersect ENT's current trading price of US$16.63 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Intersect ENT’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

View our latest analysis for Intersect ENT

What is Intersect ENT worth?

The stock seems fairly valued at the moment according to my valuation model. It’s trading around 10% below my intrinsic value, which means if you buy Intersect ENT today, you’d be paying a reasonable price for it. And if you believe the company’s true value is $18.49, then there’s not much of an upside to gain from mispricing. Is there another opportunity to buy low in the future? Since Intersect ENT’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

What does the future of Intersect ENT look like?

earnings-and-revenue-growth
NasdaqGM:XENT Earnings and Revenue Growth June 8th 2021

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 61% over the next couple of years, the future seems bright for Intersect ENT. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? It seems like the market has already priced in XENT’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?

Are you a potential investor? If you’ve been keeping an eye on XENT, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. While conducting our analysis, we found that Intersect ENT has 2 warning signs and it would be unwise to ignore these.

If you are no longer interested in Intersect ENT, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

When trading Intersect ENT or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.